Literature DB >> 29793969

Clinical Pharmacogenomics: Applications in Nephrology.

Solomon M Adams1, Karryn R Crisamore1, Philip E Empey2,3.   

Abstract

Pharmacogenomics is a tool for practitioners to provide precision pharmacotherapy using genomics. All providers are likely to encounter genomic data in practice with the expectation that they are able to successfully apply it to patient care. Pharmacogenomics tests for genetic variations in genes that are responsible for drug metabolism, transport, and targets of drug action. Variations can increase the risk for drug toxicity or poor efficacy. Pharmacogenomics can, therefore, be used to help select the best medication or aid in dosing. Nephrologists routinely treat cardiovascular disease and manage patients after kidney transplantation, two situations for which there are several high-evidence clinical recommendations for commonly used anticoagulants, antiplatelets, statins, and transplant medications. Successful use of pharmacogenomics in practice requires that providers are familiar with how to access and use pharmacogenomics resources. Similarly, clinical decision making related to whether to use existing data, whether to order testing, and if data should be used in practice is needed to deliver precision medicine. Pharmacogenomics is applicable to virtually every medical specialty, and nephrologists are well positioned to be implementation leaders.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Anticoagulants; Cardiovascular Diseases; Clinical Decision-making; Drug-related Side Effects and Adverse Reactions; Genetic Variation; Genomics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nephrologists; Patient Care; Pharmacogenetics; Pharmacogenomics; Precision Medicine; drug metabolism; drug transporter; kidney transplantation; nephrology; pharmacokinetics

Year:  2018        PMID: 29793969      PMCID: PMC6218819          DOI: 10.2215/CJN.02730218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  68 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

2.  A review of warfarin dosing and monitoring.

Authors:  M Kuruvilla; C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-07

3.  The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Authors:  K A Kim; P W Park; S J Hong; J-Y Park
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

Review 4.  Severe cutaneous adverse drug reactions.

Authors:  Wen-Hung Chung; Chuang-Wei Wang; Ro-Lan Dao
Journal:  J Dermatol       Date:  2016-05-06       Impact factor: 4.005

Review 5.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

6.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

7.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson
Journal:  JACC Cardiovasc Interv       Date:  2017-11-01       Impact factor: 11.195

8.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Authors:  Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee
Journal:  Clin Pharmacol Ther       Date:  2018-01-30       Impact factor: 6.875

Review 9.  Web resources for pharmacogenomics.

Authors:  Guoqing Zhang; Yunsheng Zhang; Yunchao Ling; Jia Jia
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-02-19       Impact factor: 7.691

Review 10.  Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.

Authors:  Shabbir Ahmed; Zhan Zhou; Jie Zhou; Shu-Qing Chen
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-10-08       Impact factor: 7.691

View more
  8 in total

1.  Pharmacogenomic analysis of a genetically distinct Indigenous population.

Authors:  Arvind Jaya Shankar; Sudhir Jadhao; Wendy Hoy; Simon J Foote; Hardip R Patel; Vinod Scaria; Brendan J McMorran; Shivashankar H Nagaraj
Journal:  Pharmacogenomics J       Date:  2021-11-25       Impact factor: 3.245

Review 2.  A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease.

Authors:  Maria Tziastoudi; Georgios Pissas; Georgios Raptis; Christos Cholevas; Theodoros Eleftheriadis; Evangelia Dounousi; Ioannis Stefanidis; Theoharis C Theoharides
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

3.  Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?

Authors:  Ehsan Nobakht; Muralidharan Jagadeesan; Rohan Paul; Jonathan Bromberg; Sherry Dadgar
Journal:  Transplant Direct       Date:  2021-01-07

Review 4.  How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside.

Authors:  Doloretta Piras; Nicola Lepori; Gianfranca Cabiddu; Antonello Pani
Journal:  J Pers Med       Date:  2022-01-31

Review 5.  Drug toxicity in the proximal tubule: new models, methods and mechanisms.

Authors:  Andrew M Hall; Francesco Trepiccione; Robert J Unwin
Journal:  Pediatr Nephrol       Date:  2021-05-28       Impact factor: 3.651

6.  VARIDT 1.0: variability of drug transporter database.

Authors:  Jiayi Yin; Wen Sun; Fengcheng Li; Jiajun Hong; Xiaoxu Li; Ying Zhou; Yinjing Lu; Mengzhi Liu; Xue Zhang; Na Chen; Xiuping Jin; Jia Xue; Su Zeng; Lushan Yu; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

7.  Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).

Authors:  Jeeyun A Kim; Rachel Ceccarelli; Christine Y Lu
Journal:  J Pers Med       Date:  2021-03-04

8.  Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study.

Authors:  Fei Yee Lee; Farida Islahudin; Aina Yazrin Ali Nasiruddin; Abdul Halim Abdul Gafor; Hin-Seng Wong; Sunita Bavanandan; Shamin Mohd Saffian; Adyani Md Redzuan; Nurul Ain Mohd Tahir; Mohd Makmor-Bakry
Journal:  J Pers Med       Date:  2021-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.